Live Stock Coverage: How Analysts Feel About Kindred Biosciences Inc After Today’s Significant Increase?

Live Stock Coverage: How Analysts Feel About Kindred Biosciences Inc After Today's Significant Increase?

The stock of Kindred Biosciences Inc (NASDAQ:KIN) is a huge mover today! The stock increased 7.14% or $0.3 on November 23, hitting $4.5. About 75,092 shares traded hands. Kindred Biosciences Inc (NASDAQ:KIN) has risen 22.62% since April 22, 2016 and is uptrending. It has outperformed by 17.21% the S&P500.
The move comes after 9 months positive chart setup for the $87.43 million company. It was reported on Nov, 24 by We have $4.68 PT which if reached, will make NASDAQ:KIN worth $3.50 million more.

Analysts await Kindred Biosciences Inc (NASDAQ:KIN) to report earnings on March, 1. They expect $-0.36 EPS, down 12.50% or $0.04 from last year’s $-0.32 per share. After $-0.29 actual EPS reported by Kindred Biosciences Inc for the previous quarter, Wall Street now forecasts 24.14% negative EPS growth.

Kindred Biosciences Inc (NASDAQ:KIN) Ratings Coverage

Out of 3 analysts covering Kindred Biosciences (NASDAQ:KIN), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Kindred Biosciences has been the topic of 3 analyst reports since November 17, 2015 according to StockzIntelligence Inc. BMO Capital Markets downgraded Kindred Biosciences Inc (NASDAQ:KIN) on Tuesday, November 17 to “Market Perform” rating. Ladenburg Thalmann initiated the shares of KIN in a report on Tuesday, November 1 with “Buy” rating. The stock of Kindred Biosciences Inc (NASDAQ:KIN) has “Sector Weight” rating given on Friday, November 18 by KeyBanc Capital Markets.

According to Zacks Investment Research, “Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.”

Insitutional Activity: The institutional sentiment decreased to 0.67 in 2016 Q2. Its down 2.46, from 3.13 in 2016Q1. The ratio turned negative, as 3 funds sold all Kindred Biosciences Inc shares owned while 5 reduced positions. 4 funds bought stakes while 21 increased positions. They now own 25.54 million shares or 107.22% more from 12.33 million shares in 2016Q1.
Deutsche Bank Ag last reported 0% of its portfolio in the stock. The Illinois-based Ariel Invs Limited Liability has invested 0.16% in Kindred Biosciences Inc (NASDAQ:KIN). Park West Asset Mngmt has 1.95M shares for 0.7% of their US portfolio. Blackrock Invest Mgmt Ltd Company last reported 0% of its portfolio in the stock. Ecor1 Capital Lc accumulated 2% or 1.43M shares. Morgan Stanley, a New York-based fund reported 28,119 shares. Moreover, Grt Cap Prns Limited Liability has 0.05% invested in Kindred Biosciences Inc (NASDAQ:KIN) for 62,300 shares. Blackrock Institutional Trust Na last reported 62,182 shares in the company. Prudential Financial has invested 0% of its portfolio in Kindred Biosciences Inc (NASDAQ:KIN). Tower Cap Limited Liability (Trc) holds 1,455 shares or 0% of its portfolio. Nationwide Fund Advisors holds 0% of its portfolio in Kindred Biosciences Inc (NASDAQ:KIN) for 8,600 shares. Goldman Sachs Grp Inc last reported 0% of its portfolio in the stock. Fmr holds 0% of its portfolio in Kindred Biosciences Inc (NASDAQ:KIN) for 219,950 shares. Bridgeway Capital Management owns 80,300 shares or 0% of their US portfolio. Lpl Fincl Limited Liability Corp, a California-based fund reported 13,925 shares.

More important recent Kindred Biosciences Inc (NASDAQ:KIN) news were published by: which released: “Kindred Biosciences to Present at 9th Annual LD Micro Investor Conference” on November 18, 2016, also published article titled: “News Kindred Biosciences Inc.KIN”, published: “Kindred Biosciences Submits Zimeta (KIND-012) New Animal Drug Application …” on February 11, 2016. More interesting news about Kindred Biosciences Inc (NASDAQ:KIN) was released by: and their article: “Kindred Biosciences Receives Approval of Effectiveness Technical Section from …” with publication date: October 04, 2016.

KIN Company Profile

Kindred Biosciences, Inc., incorporated on September 25, 2012, is a development-stage biopharmaceutical company. The Firm is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Firm is developing product candidates for over 20 indications and focused on small molecule products, and canine and feline biologics products. The Company’s biologic product candidates are based on therapies and targets, for which products have been commercialized for humans. The Firm is developing antibodies that target canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment